Edwards Lifesciences price target lowered to $82 from $86 at RBC Capital

RBC Capital analyst Shagun Singh lowered the firm’s price target on Edwards Lifesciences to $82 from $86 but keeps an Outperform rating on the shares. The company’s Q3 results were in-line, but its TAVR business was much in focus ahead of the quarter, which missed expectations despite posting double-digit ex-fx sales growth in U.S. and internationally, the analyst tells investors in a research note. Edwards Lifesciences’ Q4 guidance now implies FY23 guide to be at the low-end of the range for both sales and EPS, the firm added.